Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
CTR20170281Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Hodgkin lymphoma (HL), sponsored by Innovent Biologics. Started Apr 2017; status: completed.
02
Drugs
sintilimab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on CTR20170281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170281.